Preliminary Final Report - Year Ended 31 March 2018
Filed with ASX · · 10 pages · English
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- App 4C - March 2018 Quarterly Cash Flow Report
- Focus on Immuno-Oncology & Acquisition of 2 Drug Candidates
- S&P DJ Indices Announces March Quarterly Rebalance
- Appendix 4C - December 2017 Quarter
- Half Yearly Report and Accounts - HY ending 30 Sep 2017
Later from Amplia Therapeutics
- European Patent Granted for Innates Drug Candidate AMP-886
- Appendix 4C - June 2018 Quarter Cashflow Statement
- Response to ASX Query
- Appendix 4C - quarterly
- App 4D Half Year Accounts 30 Sep 2018
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics